FiercePharma4d
Novartis slammed for discrediting industry as 'very concerned' panel finds fault with Entresto files
Novartis’ Entresto team has earned the ire of the PMCPA. For the third time in 12 months, the U.K. drug promotion watchdog ...
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.
Novartis to pay $1B upfront for Watertown startup aiming to improve radiation treatment
Novartis is shelling out $1 billion upfront to buy a Watertown startup that's working to make radiation treatment more ...
STAT11d
Novartis’ $3 billion MorphoSys boondoggle
Oh man, there I go. Sorry, I can’t help myself. I’m fascinated by the very real possibility that Novartis, one of the largest ...
GEN12d
Novartis to Acquire Mariana for Up to $1.75B, Expanding Radiopharma Pipeline
Novartis has agreed to acquire Mariana Oncology for up to $1.75 billion, the companies said today, in a deal that would ...
Business Insider3d
Novartis' Scemblix Gets Breakthrough Designation For Chronic CML
(RTTNews) - Novartis AG (NVS) Thursday announced that the FDA has granted Breakthrough Therapy designation to Scemblix for treating adult patients with newly diagnosed Philadelphia ...
STAT11d
Novartis extends radiopharma plans with $1 billion acquisition
Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these ...
BioSpace13d
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership
Under the latest teaming between the two companies, who have worked together since 2010, Novartis will pay $180 million upfront to PeptiDream to find new radioligand therapies.
Morningstar3d
Novartis AG Registered Shares NOVN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
MarketWatch3d
Novartis Gets FDA Breakthrough Therapy Designation for Scemblix
Novartis said the U.S. drug regulator decided to expedite the development of Scemblix, to treat adults newly diagnosed with leukemia. The Swiss pharmaceutical company said the U.S. Food and Drug ...